Mineral trioxide aggregate solution inhibits osteoclast differentiation through the maintenance of osteoprotegerin expression in osteoblasts

Journal of Biomedical Materials Research - Part A

Volumn 96 A, Issue 2, 2011, Pages 358-364

  Hashiguchi, Daisuke ^a   Fukushima, Hidefumi ^a   Nakamura, Midori ^b   Morikawa, Kazumasa ^a   Yasuda, Hisataka ^c   Udagawa, Nobuyuki ^b   Maki, Kenshi ^a   Jimi, Eijiro ^a  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

^c Oriental Yeast Co Ltd   (Japan)

Author keywords

calcium; mineral trioxide aggregate; osteoblast; osteoclast; osteoprotegerin

Indexed keywords

CO-CULTURES; COMMONLY USED; IN-VITRO; INHIBITORY EFFECT; MINERAL TRIOXIDE AGGREGATE; MINERAL TRIOXIDE AGGREGATES; MOUSE BONE MARROW CELLS; OSTEOCLAST; OSTEOCLAST DIFFERENTIATION; OSTEOCLASTOGENESIS; OSTEOPROTEGERIN; PRIMARY OSTEOBLASTS; PROTEIN PRODUCTION; RECEPTOR ACTIVATOR; REPAIR MATERIALS; RESTORATIVE MATERIALS;

AGGREGATES; CALCIUM CHLORIDE; MAINTENANCE; OSTEOBLASTS; SILICATE MINERALS;

MINERALS;

BIOMEDICAL AND DENTAL MATERIALS; MINERAL TRIOXIDE AGGREGATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; CONTROLLED STUDY; CULTURE MEDIUM; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION;

ALUMINUM COMPOUNDS; ANIMALS; BONE MARROW CELLS; CALCITRIOL; CALCIUM CHLORIDE; CALCIUM COMPOUNDS; CELL DIFFERENTIATION; COCULTURE TECHNIQUES; DRUG COMBINATIONS; GENE EXPRESSION REGULATION; HUMANS; MICE; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPROTEGERIN; OXIDES; RANK LIGAND; SILICATES; SOLUTIONS;

EID: 78650441822     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32990     Document Type: Article

References (33)

1. Farsi N, Alamoudi N, Balto K, Mushayt A,. Success of mineral trioxide aggregate in pulpotomized primary molars. J Clin Pediatr Dent 2005; 29: 307-311. (Pubitemid 44152028)
2. Ford TR, Torabinejad M, Abedi HR, Bakland LK, Kariyawasam SP,. Using mineral trioxide aggregate as a pulp-capping material. J Am Dent Assoc 1996; 127: 1491-1494. (Pubitemid 126432962)
3. Eidelman E, Holan G, Fuks AB,. Mineral trioxide aggregate vs. formocresol in pulpotomized primary molars. Pediatr Dent 2001; 23: 15-18.
4. Bonson S, Jeansonne BG, Lallier TE,. Root-end filling materials alter fibroblast differentiation. J Dent Res 2004; 83: 408-413. (Pubitemid 41766098)
5. Takita T, Hayashi M, Takeichi O, Ogiso B, Suzuki N, Otsuka K, Ito K,. Effect of mineral trioxide aggregate on proliferation of cultured human dental pulp cells. Int Endod J 2006; 39: 415-422. (Pubitemid 43504420)
6. Pelliccioni GA, Ciapetti G, Cenni E, Granchi D, Nanni M, Pagani S, Giunti A,. Evaluation of osteoblast-like cell response to Proroot MTA (mineral trioxide aggregate) cement. J Mater Sci Mater Med 2004; 15: 167-173. (Pubitemid 38187056)
7. Zhu Q, Haglund R, Safavi KE, Spangberg LS,. Adhesion of human osteoblasts on root-end filling materials. J Endod 2000; 26: 404-406.
8. Nakayama A, Ogiso B, Tanabe N, Takeichi O, Matsuzaka K, Inoue T,. Behaviour of bone marrow osteoblast-like cells on mineral trioxide aggregate: Morphology and expression of type I collagen and bone-related protein mRNAs. Int Endod J 2005; 38: 203-210. (Pubitemid 40522583)
9. Gomes-Filho JE, de Faria MD, Bernabé PF, Nery MJ, Otoboni-Filho JA, Dezan-Júnior E, de Moraes Costa MM, Cannon M,. Mineral trioxide aggregate but not light-cure mineral trioxide aggregate stimulated mineralization. J Endod 2008; 34: 62-65.
10. Suda T, Nakamura I, Jimi E, Takahashi N,. Regulation of osteoclast function. J Bone Miner Res 1997; 12: 869-879. (Pubitemid 27224995)
11. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ,. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-357. (Pubitemid 30649812)
12. Nakashima T, Wada T, Penninger JM,. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003; 15: 280-287. (Pubitemid 36532608)
13. Boyle WJ, Simonet WS, Lacey DL,. Osteoclast differentiation and activation. Nature 2003; 15: 337-342.
14. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T,. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 31: 3597-3602. (Pubitemid 28173173)
15. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ,. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 17: 165-176. (Pubitemid 28180851)
16. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higasio K,. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 8: 137-142. (Pubitemid 27267548)
17. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ,. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 18: 309-319. (Pubitemid 27199902)
18. Ribeiro DA, Matsumoto MA, Duarte MA, Marques ME, Salvadori DM,. In vitro biocompatibility tests of two commercial types of mineral trioxide aggregate. Braz Oral Res 2005; 19: 183-187.
19. Fridland M, Rosado R,. Mineral trioxide aggregate (MTA) solubility and porosity with different water-to-powder ratios. J Endod 2003; 29: 814-817. (Pubitemid 38659649)
20. Maeda H, Nakano T, Tomokiyo A, Fujii S, Wada N, Monnouchi S, Hori K, Akamine A,. Mineral trioxide aggregate induces bone morphogenetic protein-2 expression and calcification in human periodontal ligament cells. J Endod 2010; 36: 647-652.
21. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T, Sato Y, Nakagawa N, Yasuda H, Mochizuki S, Gomibuchi T, Yano K, Shima N, Washida N, Tsuda E, Morinaga T, Higashio K, Ozawa H,. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247: 610-615. (Pubitemid 28418439)
22. Koh ET, McDonald F, Pitt Ford TR, Torabinejad M,. Cellular response to mineral trioxide aggregate. J Endod 1998; 24: 543-547. (Pubitemid 128704247)
23. Thomson TS, Berry JE, Somerman MJ, Kirkwood KL,. Cementoblasts maintain expression of osteocalcin in the presence of mineral trioxide aggregate. J Endod 2003; 29: 407-412.
24. Perinpanayagam H, Al-Rabeah E,. Osteoblasts interact with MTA surfaces and express Runx2. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 107: 590-596.
25. Koulaouzidou EA, Papazisis KT, Economides NA, Beltes P, Kortsaris AH,. Antiproliferative effect of mineral trioxide aggregate, zinc oxide-eugenol cement, and glass-ionomer cement against three fibroblastic cell lines. J Endod 2005; 31: 44-46. (Pubitemid 40137588)
26. Schmalz G, Hoffmann M, Weis K, Schweikl H,. Influence of albumin and collagen on the cell mortality evoked by zinc oxide-eugenol in vitro. J Endod 2000; 26: 284-287.
27. Lee YL, Lee BS, Lin FH, Yun Lin A, Lan WH, Lin CP,. Effects of physiological environments on the hydration behavior of mineral trioxide aggregate. Biomaterials 2004; 25: 787-793. (Pubitemid 37371987)
28. 4. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106: 450-456.
29. Duarte MA, Demarchi AC, Yamashita JC, Kuga MC, Fraga Sde C,. pH and calcium ion release of 2 root-end filling materials. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 345-347. (Pubitemid 36877342)
30. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T,. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-κB ligand and osteoprotegerin in osteoblasts. Endocrinology 2000; 141: 4711-4719. (Pubitemid 32055151)
31. 3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res 2004; 19: 1411-1419. (Pubitemid 41094342)
32. Thirunavukkarasu K, Halladay DL, Miles RR, Geringer CD, Onyia JE,. Analysis of regulator of G-protein signaling-2 (RGS-2) expression and function in osteoblastic cells. J Cell Biochem 2002; 85: 837-850. (Pubitemid 34462793)
33. Glass DA II, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G,. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005; 8: 751-764. (Pubitemid 40585297)